Symbols / JNJ
JNJ Chart
About
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 590.83B |
| Enterprise Value | 620.07B | Income | 26.80B | Sales | 94.19B |
| Book/sh | 33.87 | Cash/sh | 8.34 | Dividend Yield | 212.00% |
| Payout | 46.60% | Employees | 138200 | IPO | — |
| P/E | 22.23 | Forward P/E | 19.55 | PEG | — |
| P/S | 6.27 | P/B | 7.24 | P/C | — |
| EV/EBITDA | 18.33 | EV/Sales | 6.58 | Quick Ratio | 0.69 |
| Current Ratio | 1.03 | Debt/Eq | 60.50 | LT Debt/Eq | — |
| EPS (ttm) | 10.98 | EPS next Y | 12.54 | EPS Growth | 48.60% |
| Revenue Growth | 9.10% | Earnings | 2026-04-14 | ROA | 8.68% |
| ROE | 35.03% | ROIC | — | Gross Margin | 68.08% |
| Oper. Margin | 23.97% | Profit Margin | 28.46% | Shs Outstand | 2.41B |
| Shs Float | 2.41B | Short Float | 0.86% | Short Ratio | 2.11 |
| Short Interest | — | 52W High | 247.25 | 52W Low | 141.50 |
| Beta | 0.35 | Avg Volume | 8.97M | Volume | 7.65M |
| Target Price | $232.50 | Recom | Buy | Prev Close | $246.28 |
| Price | $245.17 | Change | -0.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$232.50
Mean price target
2. Current target
$245.17
Latest analyst target
3. DCF / Fair value
$124.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$245.17
Low
$155.00
High
$265.00
Mean
$232.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | main | RBC Capital | Outperform → Outperform | $255 |
| 2026-01-28 | up | Morgan Stanley | Equal-Weight → Overweight | $262 |
| 2026-01-27 | main | Freedom Capital Markets | Hold → Hold | $220 |
| 2026-01-23 | main | Guggenheim | Buy → Buy | $240 |
| 2026-01-22 | main | Citigroup | Buy → Buy | $250 |
| 2026-01-22 | main | B of A Securities | Neutral → Neutral | $221 |
| 2026-01-22 | main | TD Cowen | Buy → Buy | $250 |
| 2026-01-22 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $200 |
| 2026-01-22 | main | Wells Fargo | Overweight → Overweight | $240 |
| 2026-01-22 | main | Scotiabank | Sector Outperform → Sector Outperform | $265 |
| 2026-01-22 | main | Stifel | Hold → Hold | $220 |
| 2026-01-09 | main | Bernstein | Market Perform → Market Perform | $208 |
| 2025-12-30 | main | Barclays | Equal-Weight → Equal-Weight | $217 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $240 |
| 2025-12-15 | main | B of A Securities | Neutral → Neutral | $220 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $197 |
| 2025-12-11 | main | Citigroup | Buy → Buy | $232 |
| 2025-12-11 | main | RBC Capital | Outperform → Outperform | $230 |
| 2025-12-05 | main | Guggenheim | Buy → Buy | $227 |
| 2025-12-02 | main | Barclays | Equal-Weight → Equal-Weight | $197 |
News
RSS: Latest JNJ news- Does JNJ Stock Still Offer Value? - Forbes Mon, 23 Feb 2026 16
- Will Philadelphia Talc Verdict Reshape Johnson & Johnson's (JNJ) Legal Overhang and Earnings Resilience Narrative? - simplywall.st Wed, 25 Feb 2026 12
- Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? - The Motley Fool Wed, 04 Feb 2026 08
- TD Asset Management Inc Sells 28,172 Shares of Johnson & Johnson $JNJ - MarketBeat Wed, 25 Feb 2026 13
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) (NYSE:JNJ) - Seeking Alpha Wed, 25 Feb 2026 12
- Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone - TipRanks Mon, 23 Feb 2026 13
- Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares - TechStock² Fri, 20 Feb 2026 20
- Can J&J Sustain Its Double-Digit Oncology Growth Streak? - The Globe and Mail Wed, 25 Feb 2026 14
- Johnson & Johnson Stock On A Winning Streak: Time To Get In Or Book Profits? - Trefis Sat, 21 Feb 2026 07
- Is Johnson & Johnson Stock Outperforming the Nasdaq? - Barchart.com ue, 24 Feb 2026 13
- What's Behind The 50% Surge In JNJ Stock? - Forbes ue, 03 Feb 2026 08
- Johnson & Johnson $JNJ Shares Bought by Empirical Asset Management LLC - MarketBeat Wed, 25 Feb 2026 10
- The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson - The Motley Fool Sun, 22 Feb 2026 12
- Johnson & Johnson (JNJ) Valuation Check After New Drug Approvals And US$1b Cell Therapy Investment - simplywall.st ue, 24 Feb 2026 06
- After A 55% Surge, Is JNJ Stock Still A Buy? - Forbes Fri, 13 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1322 | 324763.0 | — | Sale at price 245.66 per share. | SCHMID TIMOTHY | Officer | — | 2026-02-20 00:00:00 | D |
| 1 | 22623 | 5527506.0 | — | Sale at price 244.20 - 244.53 per share. | SCHMID TIMOTHY | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 29554 | 2741335.0 | — | Conversion of Exercise of derivative security at price 115.67 - 129.51 per share. | SCHMID TIMOTHY | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 6197 | 1508288.0 | — | Sale at price 243.39 per share. | BROADHURST VANESSA | Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 62080 | 15109759.0 | — | Sale at price 242.70 - 243.76 per share. | SWANSON JAMES D | Chief Technology Officer | — | 2026-02-17 00:00:00 | D |
| 5 | 89654 | 21767827.0 | — | Sale at price 242.68 - 242.99 per share. | WOLK JOSEPH J | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 6 | 53931 | 13105233.0 | — | Sale at price 243.00 per share. | REED JOHN C | Officer | — | 2026-02-17 00:00:00 | D |
| 7 | 73140 | 10202710.0 | — | Conversion of Exercise of derivative security at price 162.75 - 165.89 per share. | SWANSON JAMES D | Chief Technology Officer | — | 2026-02-17 00:00:00 | D |
| 8 | 107784 | 8193223.0 | — | Conversion of Exercise of derivative security at price 115.67 - 131.94 per share. | WOLK JOSEPH J | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 9 | 54844 | 8103281.0 | — | Conversion of Exercise of derivative security at price 156.15 - 157.92 per share. | REED JOHN C | Officer | — | 2026-02-17 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.04B | -1.11B | -92.23M | -162.93M |
| TaxRateForCalcs | 0.18 | 0.16 | 0.12 | 0.15 |
| NormalizedEBITDA | 35.16B | 31.83B | 24.12B | 27.66B |
| TotalUnusualItems | 5.89B | -7.04B | -802.00M | -1.06B |
| TotalUnusualItemsExcludingGoodwill | 5.89B | -7.04B | -802.00M | -1.06B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 26.80B | 14.07B | 13.33B | 16.37B |
| ReconciledDepreciation | 7.50B | 7.34B | 7.49B | 6.97B |
| ReconciledCostOfRevenue | 30.26B | 27.47B | 26.55B | 24.60B |
| EBITDA | 41.05B | 24.78B | 23.32B | 26.61B |
| EBIT | 33.55B | 17.44B | 15.83B | 19.64B |
| NetInterestIncome | 85.00M | 577.00M | 489.00M | 214.00M |
| InterestExpense | 971.00M | 755.00M | 772.00M | 276.00M |
| InterestIncome | 1.06B | 1.33B | 1.26B | 490.00M |
| NormalizedIncome | 21.96B | 20.00B | 14.04B | 17.27B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 26.80B | 14.07B | 35.15B | 17.94B |
| TotalExpenses | 68.60B | 67.57B | 63.15B | 58.98B |
| DilutedAverageShares | 2.43B | 2.43B | 2.56B | 2.66B |
| BasicAverageShares | 2.41B | 2.41B | 2.53B | 2.61B |
| DilutedEPS | 11.03 | 5.79 | 13.72 | 6.73 |
| BasicEPS | 11.13 | 5.84 | 13.88 | 6.86 |
| DilutedNIAvailtoComStockholders | 26.80B | 14.07B | 35.15B | 17.94B |
| NetIncomeCommonStockholders | 26.80B | 14.07B | 35.15B | 17.94B |
| NetIncome | 26.80B | 14.07B | 35.15B | 17.94B |
| NetIncomeIncludingNoncontrollingInterests | 26.80B | 14.07B | 35.15B | 17.94B |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 21.83B | 1.57B |
| NetIncomeContinuousOperations | 26.80B | 14.07B | 13.33B | 16.37B |
| TaxProvision | 5.78B | 2.62B | 1.74B | 2.99B |
| PretaxIncome | 32.58B | 16.69B | 15.06B | 19.36B |
| OtherIncomeExpense | 6.89B | -5.14B | -7.44B | -1.87B |
| OtherNonOperatingIncomeExpenses | 1.00B | 1.90B | -6.63B | -810.00M |
| SpecialIncomeCharges | 5.49B | -6.75B | -802.00M | -1.06B |
| OtherSpecialCharges | -6.00B | 5.50B | 7.30B | 2.60B |
| ImpairmentOfCapitalAssets | 81.00M | 211.00M | 313.00M | 783.00M |
| RestructuringAndMergernAcquisition | 428.00M | 1.03B | 489.00M | 275.00M |
| GainOnSaleOfSecurity | 400.00M | -300.00M | -600.00M | -700.00M |
| NetNonOperatingInterestIncomeExpense | 85.00M | 577.00M | 489.00M | 214.00M |
| InterestExpenseNonOperating | 971.00M | 755.00M | 772.00M | 276.00M |
| InterestIncomeNonOperating | 1.06B | 1.33B | 1.26B | 490.00M |
| OperatingIncome | 25.60B | 21.25B | 22.01B | 21.01B |
| OperatingExpense | 38.34B | 40.10B | 36.60B | 34.38B |
| ResearchAndDevelopment | 14.66B | 17.23B | 15.09B | 14.13B |
| SellingGeneralAndAdministration | 23.68B | 22.87B | 21.51B | 20.25B |
| GeneralAndAdministrativeExpense | 22.87B | 21.51B | 20.25B | 20.12B |
| OtherGandA | 22.87B | 21.51B | 20.25B | 20.12B |
| SalariesAndWages | -900.00M | -1.40B | -1.20B | -600.00M |
| GrossProfit | 63.94B | 61.35B | 58.61B | 55.39B |
| CostOfRevenue | 30.26B | 27.47B | 26.55B | 24.60B |
| TotalRevenue | 94.19B | 88.82B | 85.16B | 79.99B |
| OperatingRevenue | 94.19B | 88.82B | 85.16B | 79.99B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 711.90M | 712.92M | 712.76M | 506.25M |
| OrdinarySharesNumber | 2.41B | 2.41B | 2.41B | 2.61B |
| ShareIssued | 3.12B | 3.12B | 3.12B | 3.12B |
| NetDebt | 28.22B | 12.53B | 7.47B | 26.75B |
| TotalDebt | 47.93B | 36.63B | 29.33B | 39.64B |
| TangibleBookValue | -17.63B | -10.33B | -1.96B | 2.27B |
| InvestedCapital | 129.48B | 108.12B | 98.11B | 116.45B |
| WorkingCapital | 1.50B | 5.57B | 7.21B | -508.00M |
| NetTangibleAssets | -17.63B | -10.33B | -1.96B | 2.27B |
| CommonStockEquity | 81.54B | 71.49B | 68.77B | 76.80B |
| TotalCapitalization | 120.98B | 102.14B | 94.66B | 103.69B |
| TotalEquityGrossMinorityInterest | 81.54B | 71.49B | 68.77B | 76.80B |
| StockholdersEquity | 81.54B | 71.49B | 68.77B | 76.80B |
| GainsLossesNotAffectingRetainedEarnings | -14.93B | -11.74B | -12.53B | -12.97B |
| OtherEquityAdjustments | -14.93B | -11.74B | -12.53B | -12.97B |
| TreasuryStock | 75.62B | 75.68B | 75.66B | 41.69B |
| RetainedEarnings | 153.84B | 128.34B | 123.06B | |
| AdditionalPaidInCapital | 168.98B | 155.79B | 153.84B | 128.34B |
| CapitalStock | 3.12B | 3.12B | 3.12B | 3.12B |
| CommonStock | 3.12B | 3.12B | 3.12B | 3.12B |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 117.67B | 108.61B | 98.78B | 110.57B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 63.54B | 58.29B | 52.50B | 54.77B |
| OtherNonCurrentLiabilities | 9.87B | 17.55B | 13.40B | 10.15B |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 2.90B | ||
| EmployeeBenefits | 6.96B | 7.25B | 7.15B | 6.54B |
| TradeandOtherPayablesNonCurrent | 486.00M | 390.00M | 2.88B | 4.31B |
| NonCurrentDeferredLiabilities | 6.79B | 2.45B | 3.19B | 3.99B |
| NonCurrentDeferredTaxesLiabilities | 6.79B | 2.45B | 3.19B | 3.99B |
| LongTermDebtAndCapitalLeaseObligation | 39.44B | 30.65B | 25.88B | 26.89B |
| LongTermDebt | 39.44B | 30.65B | 25.88B | 26.89B |
| CurrentLiabilities | 54.13B | 50.32B | 46.28B | 55.80B |
| OtherCurrentLiabilities | 3.59B | |||
| CurrentDebtAndCapitalLeaseObligation | 8.49B | 5.98B | 3.45B | 12.76B |
| CurrentDebt | 8.49B | 5.98B | 3.45B | 12.76B |
| OtherCurrentBorrowings | 8.49B | 5.98B | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.53B | 4.13B | 3.99B | 3.05B |
| PayablesAndAccruedExpenses | 41.10B | 40.21B | 38.84B | 36.41B |
| CurrentAccruedExpenses | 27.72B | 26.13B | 26.21B | 24.30B |
| Payables | 13.38B | 14.08B | 12.62B | 12.11B |
| TotalTaxPayable | 1.39B | 3.77B | 2.99B | 2.22B |
| IncomeTaxPayable | 1.39B | 3.77B | 2.99B | 2.22B |
| AccountsPayable | 11.99B | 10.31B | 9.63B | 9.89B |
| TotalAssets | 199.21B | 180.10B | 167.56B | 187.38B |
| TotalNonCurrentAssets | 143.59B | 124.21B | 114.06B | 132.08B |
| OtherNonCurrentAssets | 14.37B | 11.41B | 14.15B | 30.62B |
| NonCurrentDeferredAssets | 6.87B | 10.46B | 9.28B | 8.95B |
| NonCurrentDeferredTaxesAssets | 6.87B | 10.46B | 9.28B | 8.95B |
| GoodwillAndOtherIntangibleAssets | 99.17B | 81.82B | 70.73B | 74.54B |
| OtherIntangibleAssets | 50.40B | 37.62B | 34.17B | 38.49B |
| Goodwill | 48.77B | 44.20B | 36.56B | 36.05B |
| NetPPE | 23.17B | 20.52B | 19.90B | 17.98B |
| AccumulatedDepreciation | -31.20B | -28.25B | -27.88B | -25.55B |
| GrossPPE | 54.36B | 48.77B | 47.78B | 43.53B |
| ConstructionInProgress | 7.36B | 6.29B | 5.63B | 4.68B |
| MachineryFurnitureEquipment | 32.87B | 29.44B | 28.98B | 26.60B |
| BuildingsAndImprovements | 13.43B | 12.32B | 12.38B | 11.47B |
| LandAndImprovements | 701.00M | 718.00M | 795.00M | 784.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 55.62B | 55.89B | 53.49B | 55.29B |
| OtherCurrentAssets | 3.70B | |||
| AssetsHeldForSaleCurrent | 0.00 | 5.83B | ||
| PrepaidAssets | 3.70B | |||
| Inventory | 14.19B | 12.44B | 11.18B | 10.27B |
| FinishedGoods | 7.83B | 7.29B | 6.87B | 6.97B |
| WorkInProcess | 3.83B | 2.81B | 1.95B | 1.58B |
| RawMaterials | 2.53B | 2.34B | 2.35B | 1.72B |
| Receivables | 21.33B | 18.93B | 19.39B | 16.91B |
| OtherReceivables | 4.15B | 4.08B | 4.51B | 2.88B |
| AccountsReceivable | 17.18B | 14.84B | 14.87B | 14.04B |
| AllowanceForDoubtfulAccountsReceivable | -183.00M | -167.00M | -166.00M | -169.00M |
| GrossAccountsReceivable | 17.36B | 15.01B | 15.04B | 14.21B |
| CashCashEquivalentsAndShortTermInvestments | 20.10B | 24.52B | 22.93B | 22.28B |
| OtherShortTermInvestments | 393.00M | 417.00M | 1.07B | 9.39B |
| CashAndCashEquivalents | 19.71B | 24.11B | 21.86B | 12.89B |
| CashEquivalents | 16.41B | 21.19B | 18.52B | 9.20B |
| CashFinancial | 3.30B | 2.92B | 3.34B | 3.69B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 19.31B | 18.06B | 17.78B | 17.18B |
| RepurchaseOfCapitalStock | -5.95B | -2.43B | -5.05B | -6.04B |
| RepaymentOfDebt | -14.09B | -11.89B | -24.52B | -8.68B |
| IssuanceOfDebt | 23.72B | 21.94B | 21.79B | 16.14B |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 4.24B | 0.00 |
| CapitalExpenditure | -5.22B | -6.21B | -5.01B | -4.01B |
| InterestPaidSupplementalData | 1.98B | 1.99B | 1.84B | 982.00M |
| IncomeTaxPaidSupplementalData | 6.54B | 6.71B | 8.57B | 5.22B |
| EndCashPosition | 19.71B | 24.11B | 21.86B | 14.13B |
| BeginningCashPosition | 24.11B | 21.86B | 14.13B | 14.49B |
| EffectOfExchangeRateChanges | 201.00M | -289.00M | -112.00M | -312.00M |
| ChangesInCash | -4.60B | 2.54B | 7.84B | -48.00M |
| FinancingCashFlow | -5.54B | -3.13B | -15.82B | -8.87B |
| CashFlowFromContinuingFinancingActivities | -5.54B | -3.13B | -15.82B | -8.87B |
| NetOtherFinancingCharges | -260.00M | 234.00M | -1.60B | 65.00M |
| ProceedsFromStockOptionExercised | 3.42B | 838.00M | 1.09B | 1.33B |
| CashDividendsPaid | -12.38B | -11.82B | -11.77B | -11.68B |
| CommonStockDividendPaid | -12.38B | -11.82B | -11.77B | -11.68B |
| NetCommonStockIssuance | -5.95B | -2.43B | -813.00M | -6.04B |
| CommonStockPayments | -5.95B | -2.43B | -5.05B | -6.04B |
| CommonStockIssuance | 0.00 | 0.00 | 4.24B | 0.00 |
| NetIssuancePaymentsOfDebt | 9.64B | 10.05B | -2.73B | 7.45B |
| NetShortTermDebtIssuance | 2.26B | 5.81B | -1.18B | 9.58B |
| ShortTermDebtPayments | -12.33B | -9.46B | -22.97B | -6.55B |
| ShortTermDebtIssuance | 14.59B | 15.28B | 21.79B | 16.13B |
| NetLongTermDebtIssuance | 7.38B | 4.24B | -1.55B | -2.13B |
| LongTermDebtPayments | -1.76B | -2.42B | -1.55B | -2.13B |
| LongTermDebtIssuance | 9.14B | 6.66B | 0.00 | 2.00M |
| InvestingCashFlow | -23.59B | -18.60B | 878.00M | -12.37B |
| CashFlowFromContinuingInvestingActivities | -23.59B | -18.60B | 878.00M | -12.37B |
| NetOtherInvestingChanges | -1.57B | 2.02B | -2.59B | 65.00M |
| NetInvestmentPurchaseAndSale | 741.00M | 736.00M | 8.48B | 9.22B |
| SaleOfInvestment | 1.66B | 2.46B | 19.39B | 41.61B |
| PurchaseOfInvestment | -920.00M | -1.73B | -10.91B | -32.38B |
| NetBusinessPurchaseAndSale | -17.54B | -15.15B | 0.00 | -17.65B |
| PurchaseOfBusiness | -17.54B | -15.15B | 0.00 | -17.65B |
| NetIntangiblesPurchaseAndSale | -385.00M | -1.78B | -470.00M | 0.00 |
| PurchaseOfIntangibles | -385.00M | -1.78B | -470.00M | 0.00 |
| NetPPEPurchaseAndSale | -4.83B | -4.42B | -4.54B | -4.01B |
| PurchaseOfPPE | -4.83B | -4.42B | -4.54B | -4.01B |
| OperatingCashFlow | 24.53B | 24.27B | 22.79B | 21.19B |
| CashFlowFromContinuingOperatingActivities | 24.53B | 24.27B | 22.79B | 21.19B |
| ChangeInWorkingCapital | -12.72B | 1.84B | 2.51B | -4.01B |
| ChangeInOtherCurrentLiabilities | -5.70B | 33.00M | 5.59B | -1.98B |
| ChangeInOtherCurrentAssets | -6.17B | 1.72B | -3.48B | 687.00M |
| ChangeInPayablesAndAccruedExpense | 2.38B | 1.62B | 2.35B | 1.10B |
| ChangeInInventory | -1.45B | -1.13B | -1.32B | -2.53B |
| ChangeInReceivables | -1.78B | -406.00M | -624.00M | -1.29B |
| ChangesInAccountReceivables | -1.78B | -406.00M | -624.00M | -1.29B |
| OtherNonCashItems | 109.00M | 1.84B | 483.00M | |
| StockBasedCompensation | 1.35B | 1.18B | 1.16B | 1.14B |
| ProvisionandWriteOffofAssets | -1.00M | 11.00M | 0.00 | -17.00M |
| AssetImpairmentCharge | 204.00M | 405.00M | 1.29B | 1.22B |
| DeferredTax | 1.54B | -2.18B | -4.19B | -1.66B |
| DeferredIncomeTax | 1.54B | -2.18B | -4.19B | -1.66B |
| DepreciationAmortizationDepletion | 7.50B | 7.34B | 7.49B | 6.97B |
| DepreciationAndAmortization | 7.50B | 7.34B | 7.49B | 6.97B |
| OperatingGainsLosses | -263.00M | -226.00M | -21.10B | -380.00M |
| GainLossOnSaleOfBusiness | -263.00M | -226.00M | -21.10B | -380.00M |
| NetIncomeFromContinuingOperations | 26.80B | 14.07B | 35.15B | 17.94B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for JNJ
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|